Filed by Azur Pharma Limited

Pursuant to Rule 425 under The Securities Act of 1933

And Deemed Filed Pursuant to Rule 14a-12

Under the Securities Exchange Act of 1934

Subject Company: Jazz Pharmaceuticals, Inc.

Commission File Number: 001-33500

Date: September 19, 2011

The following is a slide presentation relating to the proposed transactions described therein that was made available beginning on September 19, 2011.

Jazz Pharmaceuticals and Azur Pharma A Compelling Strategic Combination Bruce Cozadd, Chairman and CEO

2 Forward-Looking Statements "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements, including, but not limited to, statements related to the anticipated consummation of the business combination transaction between Jazz Pharmaceuticals and Azur Pharma and the timing and benefits thereof, the combined company’s, and each respective company’s, strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, anticipated product portfolio, development programs, intellectual property and tax position, management structure, and other statements that are not historical facts.  These forward- looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Jazz Pharmaceuticals’ ability to complete the transaction on the proposed terms and schedule; risks associated with business combination transactions, such as the risk that the businesses will not be integrated successfully or that such integration may be more difficult, time- consuming or costly than expected; risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed transaction; disruption from the proposed transaction, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; the calculations of, and factors that may impact the calculations of, the acquisition price in connection with the proposed merger and the allocation of such acquisition price to the net assets acquired in accordance with applicable accounting rules and methodologies; and the possibility that if the combined company does not achieve the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of the combined company’s shares could decline, as well as other risks related to Jazz Pharmaceuticals’ business, including Jazz  competition, including potential generic competition; Jazz Pharmaceuticals’ dependence on single source suppliers and manufacturers; the ability of Jazz Pharmaceuticals to protect its intellectual property and defend its patents; regulatory obligations and oversight; Jazz Pharmaceuticals cash flow; and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Jazz Pharmaceuticals’ SEC filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2011.  Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or changes in its expectations. Pharmaceuticals’ dependence on sales of Xyrem and its ability to increase sales of its Xyrem and Luvox CR products;

3 Forward-Looking Statements Additional Information and Where to Find It In connection with the proposed transaction, Jazz Pharmaceuticals and Azur Pharma will be filing documents with the SEC, including the filing by Jazz Pharmaceuticals of a preliminary and definitive proxy statement/prospectus relating to the proposed transaction and the filing by Azur Pharma of a registration statement on Form S-4 that will include the proxy statement/prospectus relating to the proposed transaction.  After the registration statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to Jazz Pharmaceuticals stockholders in connection with the proposed transaction.  INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND THE RELATED PRELIMINARY AND DEFINITIVE PROXY/PROSPECTUS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT JAZZ PHARMACEUTICALS, AZUR PHARMA AND THE PROPOSED TRANSACTION.  Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC’s web site at www.sec.gov, by directing a request to Jazz Pharmaceuticals’ Investor Relations department at Jazz Pharmaceuticals, Inc., Attention: Investor Relations, 3180 Porter Drive, Palo Alto, California 94304, or to Jazz Pharmaceuticals’ Investor Relations department at 650-496-2800 or by email to investorinfo@jazzpharma.com. Investors and security holders may obtain free copies of the documents filed with the SEC on Jazz Pharmaceuticals’ website at www.jazzpharmaceuticals.com under the heading “Investors” and then under the heading “SEC Filings.”  Jazz Pharmaceuticals and its directors and executive officers and Azur Pharma and its directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of Jazz Pharmaceuticals in connection with the proposed transaction.  Information regarding the special interests of these directors and executive officers in the proposed transaction will be included in the proxy statement/prospectus described above.  Additional information regarding the directors and executive officers of Jazz Pharmaceuticals is also included in Jazz Pharmaceuticals’ proxy statement for its 2011 Annual Meeting of Stockholders, which was filed with the SEC on April 12, 2011.  These documents are available free of charge at the SEC’s web site at www.sec.gov and from Investor Relations at Jazz Pharmaceuticals as described above.   This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.   For full prescribing information refer to product websites.

4 Jazz Pharmaceuticals’ mission is to improve patients’ lives by identifying, developing and commercializing valuable pharmaceutical products in focused therapeutic areas Building Shareholder Value by Focusing on Patients

5 Strategy to Build Shareholder Value Grow Xyrem sales in current indications Increased focus on achieving full potential 1 Maintain entrepreneurial, ownership culture at the company 4 Make disciplined resource allocation decisions Acquire additional marketed or close to approval products Leverage our expertise and infrastructure 2 Pursue lower risk development of specialty products Invest percentage of sales longer-term 3

6 Strategic Benefits • Diversified portfolio of CNS and women’s health products • Increased scale and platform for growth • Resources to invest in future pipeline and strong franchise management opportunities • Stronger, enhanced management team Projected Financial Benefits • Accretive transaction 1 • Revenues >$475M and cash flow >$200M in first 12 months • ~$250M cash at closing 2 • Strong balance sheet with no debt 1 Accretion for Jazz Pharmaceuticals shareholders is on a  fully-taxed adjusted EPS basis. Adjusted EPS is a non-GAAP financial measure that excludes certain items from GAAP EPS. 2 Pro forma estimate as of Jan 1, 2012. Compelling Strategic and Financial Benefits Jazz Pharmaceuticals plc Ireland

7 Jazz Pharmaceuticals plc • 12 products currently marketed in US • >$475 million in revenues in first 12 months • >$200 million in cash generated in first 12 months • Jazz Pharmaceuticals: slightly under 80%; Azur Pharma: slightly over 20% • Combined capitalization approximately 60M shares fully diluted at closing • Jazz Pharmaceuticals board represented funds entered into voting agreements (~43% of shares) • 99% of Azur shareholders entered into agreement to take necessary actions • Current directors of Jazz Pharmaceuticals • Seamus Mulligan (Chairman and CEO, Azur Pharma) Portfolio & Financial Projections Ownership in Combined Company Shareholder Votes Board of Directors • Bruce Cozadd, Chairman and CEO • Kate Falberg, CFO • Seamus Mulligan, Chief Business Officer, International Business Development • Azur executives join JPI executives in leadership roles Management Anticipated Closing: 1Q12

8 2011 Estimated Revenues Stand Alone Jazz Pharmaceuticals, Inc. Pro forma Jazz Pharmaceuticals plc A Growing, Diversified Product Portfolio Luvox CR 13% Xyrem 87% Xyrem 63% Luvox CR 9% Prialt 6% Women’s Health 10% Other CNS 1% FazaClo LD 8% FazaClo HD 3%

Azur Pharma Overview Seamus Mulligan, Chairman and CEO Eunan Maguire, President, North America

Azur Pharma • Leveraging extensive industry network and business development expertise • Assembling and commercializing a diversified product portfolio in specialty therapeutic areas • Investing in lower-risk development projects through life cycle management initiatives • Establishing a highly efficient corporate structure which maximizes cash flow available to fund growth Azur Pharma is a specialty focused pharmaceutical company formed in 2005 that has created a successful business by:

Azur Pharma – Compelling Fit With Jazz Pharmaceuticals $0 $10 $20 $30 $40 $50 $60 $70 $80 $90 $100 2006 2007 2008 2009 2010 • Strong commercial focus and expertise in CNS and women’s health • Approximately 170 employees: — 105 people in 3 US sales forces across pain, psychiatry and women’s health — 16 person medical affairs team — 50 people in home office (18 Dublin; 32 Philadelphia) • Lower risk pipeline of line extensions for clozapine franchise and LCM programs for key women’s health brands 11 CNS Women’s Health Net Sales (Millions)

Prialt - for Chronic Pain • 2010 net sales of $20M (marketed by Azur since May 2010) • Only non-opioid intrathecal (IT) analgesic for severe chronic pain • Compelling growth opportunity with business characteristics similar to Xyrem: – Requires high touch sales capability with heavy clinical emphasis – Currently used in less than 3% of available pain market pumps – Limited competitive threats and multiple years of patent and other protection • European rights licensed to Eisai; Azur retains ROW rights 12 1. See full prescribing information on website 1

FazaClo – for Treatment Resistant Schizophrenia • 2010 net sales of $37M • Orally disintegrating clozapine tablets approved for management of treatment resistant schizophrenia • 10% prescription share despite largely generic clozapine market • FazaClo High Dose (HD) launched September 2010 – More than 20% switched from Low Dose (LD) as of 2Q11 – Dosing flexibility and lower pill burden • Generics filed to FazaClo – settlement with Teva with potential launch of lower dosage product in 2Q12 and higher dosage in 2015 • Additional clozapine line extensions in development 13 1. See full prescribing information on website 1

14 • Diversified and balanced set of six products 1 with 2010 net sales of $27M • Significant growth opportunity driven by Elestrin 1 , a topical gel ERT therapy - Patents through 2022 • Revamped Elestrin promotion model in 2010 leveraging 51 sales representatives Women’s Health Products - Targeting a Growing Market Elestrin Other Women’s Health Net Sales Contribution 1. See full prescribing information on website 0% 20% 40% 60% 80% 100% 2009 2010 2011E

15 Azur Pharma Pipeline Opportunities NAME INDICATION DESCRIPTION STATUS Clozapine Treatment resistant schizophrenia & reducing recurrent suicidal behavior risk Multiple life cycle programs Multiple Prenatal vitamins Prenatal supplements Multiple development programs Products to launch in 2011 onwards • Lower risk pipeline opportunities target clozapine and women’s health products • Benefits of future product candidates are additive

Financial Overview Kate Falberg CFO ,

17 Azur Pharma Financial Overview $0 $20 $40 $60 $80 $100 $120 Net Sales Operating Expenses EBITDA 2010 Financials 1 ($M) 2011 Estimates 1 ($M) 1. Financial results prepared in accordance with the International Financial Reporting Standards, IFRS 2. EBITDA is a non-GAAP financial measure that excludes certain items. A reconciliation of EBITDA to Operating Income is in a table included with this presentation. 3. Operating Expenses include R&D and SG&A $83M $24M 2 $0 $20 $40 $60 $80 $100 $120 Net Sales Operating Expenses EBITDA 2 $37M Product Gross Margin: 80-85% 3 3

• Sourcing of new products for all markets • Potential expansion into Europe Benefits of New Corporate Structure Access to international capital markets and business development opportunities • Sales, marketing, and clinical/medical science liaison organizations • Multi-product supply chain management • BD executives with demonstrated success Enhanced management capabilities • Enhanced ability to attract and retain key talent Additional locations (Philadelphia, Dublin) Parent company in Ireland expected to license, develop and acquire existing and new products 18

19 Accretive Transaction and NOLs Preserved • Transaction expected to be accretive to Jazz Pharmaceuticals, Inc. 2012 Adjusted EPS on a fully taxed basis • No operating cost synergies assumed • Reversal of valuation allowance on deferred tax assets – Would result in significant non-cash GAAP tax benefit, excluded from Adjusted EPS – Tax provision would apply subsequently • Stand alone, JPI would record taxes at ~40% – Jazz Pharmaceuticals plc pro forma expected tax rate percentage in mid-20s – 2012 a transition year for taxes 1. Adjusted EPS is a non-GAAP financial measure that excludes certain items from GAAP EPS. 2. A valuation allowance currently reduces the deferred tax assets to the amount that is more likely than not to be realized.  While the reversal criteria is not expected to be satisfied in 3Q11, Jazz Pharmaceuticals will continue to evaluate based on projected taxable income and other key operating factors. Financial Assumptions 2

20 Next Steps File preliminary proxy statement and S-4 Expected to close 1Q12 Transaction is subject to customary closing conditions and regulatory approvals, including: • SEC effectiveness of S-4 • Jazz Pharmaceuticals, Inc. stockholder approval • Azur approval of other necessary actions • Antitrust clearance • Transaction will be taxable to Jazz Pharmaceuticals, Inc. stockholders • Jazz Pharmaceuticals plc shares to be traded on Nasdaq

21 Strategic Benefits • Diversified portfolio of CNS and women’s health products • Increased scale and platform for growth • Resources to invest in future pipeline and strong franchise management opportunities • Stronger, enhanced management team Projected Financial Benefits • Accretive transaction • Revenues >$475M and cash flow >$200M in first 12 months • ~$250M cash at closing • Strong balance sheet with no debt 1 Accretion for Jazz Pharmaceuticals shareholders is on a  fully-taxed adjusted EPS basis. Adjusted EPS is a non-GAAP financial measure that excludes certain items from GAAP EPS. 2 Pro forma estimate as of Jan 1, 2012. Compelling Strategic and Financial Benefits Jazz Pharmaceuticals plc Ireland 2 1

23 Azur Pharma 1 Reconciliation of EBITDA to Operating Income (In millions) EBITDA Subtract: Depreciation & Amortization Stock-based compensation expense Operating Income $23.8 16.5 0.3 $7.0 FY 2009 1. Financial statements have been prepared in accordance with the International Financial Reporting Standards, IFRS 2010